- Home
- ABSI vs PRQR Comparison
ABSI vs PRQR Comparison
Compare ABSI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- PRQR
- Stock Information
- Founded
- ABSI 2011
- PRQR 2012
- Country
- ABSI United States
- PRQR Netherlands
- Employees
- ABSI N/A
- PRQR N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- PRQR Health Care
- Exchange
- ABSI Nasdaq
- PRQR Nasdaq
- Market Cap
- ABSI 338.0M
- PRQR 179.1M
- IPO Year
- ABSI 2021
- PRQR 2014
- Fundamental
- Price
- ABSI $2.57
- PRQR $2.35
- Analyst Decision
- ABSI Strong Buy
- PRQR Strong Buy
- Analyst Count
- ABSI 4
- PRQR 8
- Target Price
- ABSI $8.75
- PRQR $8.88
- AVG Volume (30 Days)
- ABSI 4.2M
- PRQR 346.0K
- Earning Date
- ABSI 08-13-2025
- PRQR 08-07-2025
- Dividend Yield
- ABSI N/A
- PRQR N/A
- EPS Growth
- ABSI N/A
- PRQR N/A
- EPS
- ABSI N/A
- PRQR N/A
- Revenue
- ABSI $4,815,000.00
- PRQR $21,212,711.00
- Revenue This Year
- ABSI $81.76
- PRQR N/A
- Revenue Next Year
- ABSI $287.79
- PRQR N/A
- P/E Ratio
- ABSI N/A
- PRQR N/A
- Revenue Growth
- ABSI N/A
- PRQR 85.91
- 52 Week Low
- ABSI $2.01
- PRQR $1.07
- 52 Week High
- ABSI $6.33
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- ABSI 42.24
- PRQR 71.45
- Support Level
- ABSI $2.54
- PRQR $2.10
- Resistance Level
- ABSI $2.92
- PRQR $2.51
- Average True Range (ATR)
- ABSI 0.15
- PRQR 0.15
- MACD
- ABSI -0.00
- PRQR 0.03
- Stochastic Oscillator
- ABSI 18.60
- PRQR 82.41
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.